1-3 of 3
Pierre Fustier
Close
Sort by
Journal Articles

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Herve Ghesquieres, Krimo Bouabdallah, Marc Andre, Philippe Quittet, Cecile Borel, Aspasia Stamatoulas Bastard, Michael Gilbertson, Fabien Le Bras, Catherine Thieblemont, Baptiste Delapierre, Mohamed Touati, Pierre Feugier, Julien Lazarovici, Nadine Morineau, Thomas Gastinne, Isabelle Chaillol, Rod Ramchandren, Harsh Shah, Dipenkumar Modi, Heather Allewelt, Pierre Fustier, Jianfeng Xu, Amit Agarwal, Franck Morschhauser, Cedric Rossi
Journal: Blood
Blood (2023) 142 (Supplement 1): 1717.
https://doi.org/10.1182/blood-2023-188545
Published: 2023
Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Marek Trněný, MD, John P. Leonard, MD, Huilai Zhang, MD, Grzegorz Nowakowski, MD, Koji Izutsu, MD PhD, Nathan H. Fowler, MD, Catherine Thieblemont, MD PhD, Pier Luigi Zinzani, MD PhD, Stacey Kalambakas, MD, Myron Czuczman, Pierre Fustier, PhD, Chengqing Wu, PhD, John G. Gribben, MD DSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 347.
https://doi.org/10.1182/blood-2019-122461
Published: 2019
Journal Articles

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

John P. Leonard, MD, Marek Trněný, Koji Izutsu, MDPhD, Nathan H. Fowler, MD, Xiaonan Hong, MD, Jun Zhu, Huilai Zhang, MDPhD, Fritz Offner, MD, Adriana Scheliga, MD, Grzegorz S. Nowakowski, MD, Antonio Pinto, MD, Francesca Re, MDPhD, Laura Maria Fogliatto, MD, Phillip Scheinberg, MD, Ian W. Flinn, MD PhD, Cláudia Moreira, MD, David Liu, MDPhD, Stacey Kalambakas, MD, Pierre Fustier, PhD, Chengqing Wu, PhD, John G. Gribben
Journal: Blood
Blood (2018) 132 (Supplement 1): 445.
https://doi.org/10.1182/blood-2018-99-110861
Published: 2018